MorphoSys AG Current Ratio 2018-2021 | MOR

MorphoSys AG current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
MorphoSys AG Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.51B $0.25B 6.14
2021-03-31 $1.52B $0.24B 6.22
2020-12-31 $1.38B $0.23B 6.02
2020-09-30 $1.00B $0.20B 5.02
2020-06-30 $1.02B $0.19B 5.41
2020-03-31 $1.19B $0.09B 12.87
2019-12-31 $0.34B $0.07B 4.93
2019-09-30 $0.47B $0.06B 7.80
2019-06-30 $0.44B $0.06B 7.62
2019-03-31 $0.42B $0.05B 7.75
2018-12-31 $0.46B $0.05B 8.47
2018-09-30 $0.53B $0.05B 11.51
2018-06-30 $0.47B $0.05B 9.66
2018-03-31 $0.39B $0.05B 7.45
2017-12-31 $0.39B $0.05B 7.14
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.579B $0.374B
MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company's proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00